schliessen

Filtern

 

Bibliotheken

First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.(Hematologic Malignancies)(Report)

BACKGROUND: Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a distinct subtype of non-Hodgkin lymphoma in which the upper aerodigestive tract is the most commonly involved site. To date, optimal treatment strategies and prognosis for patients with ENKTL have not been fully defined.... Full description

Journal Title: Cancer Jan 15, 2013, Vol.119(2), p.348(8)
Main Author: Wang, Liang
Other Authors: Wang, Zhi - Hui , Chen, Xiao - Qin , Li, Ya - Jun , Wang, Ke - Feng , Xia, Yun - Fei , Xia, Zhong - Jun
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0008-543X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: gale_ofa317369772
title: First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.(Hematologic Malignancies)(Report)
format: Article
creator:
  • Wang, Liang
  • Wang, Zhi - Hui
  • Chen, Xiao - Qin
  • Li, Ya - Jun
  • Wang, Ke - Feng
  • Xia, Yun - Fei
  • Xia, Zhong - Jun
subjects:
  • T Cell Lymphoma -- Research
  • T Cell Lymphoma -- Drug Therapy
  • T Cell Lymphoma -- Patient Outcomes
  • Antineoplastic Agents -- Research
  • Antineoplastic Agents -- Dosage And Administration
ispartof: Cancer, Jan 15, 2013, Vol.119(2), p.348(8)
description: BACKGROUND: Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a distinct subtype of non-Hodgkin lymphoma in which the upper aerodigestive tract is the most commonly involved site. To date, optimal treatment strategies and prognosis for patients with ENKTL have not been fully defined. METHODS: This prospective study was conducted to evaluate the efficacy and safety profiles of first-line combined gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE ENKTL. The primary endpoints were the complete response rate, the objective response rate, and toxicities. Secondary endpoints were overall survival and progression-free survival. RESULTS: Twenty-seven patients with newly diagnosed ENKTL were enrolled and completed the entire course of treatment. At the end of treatment, the overall response rate was 96.3%, including 20 patients (74.1%) who attained a complete response and 6 patients (22.2%) who attained a partial response. No patients developed disease progression during therapy. Grade 1 and 2 toxicities were frequent during GELOX, but grade 3 and 4 toxicities were few, and no treatment-related deaths occurred. At a median follow-up of 27.37 months, 7 patients (25.9%) experienced disease progression, and 4 of those patients died of disease. The rates of 2-year overall and progression-free survival were both 86%, and patients who attained a complete response at the end of treatment had significantly longer progression-free survival (P = .012) and overall survival (P = .021) than patients who did not attain a complete response. CONCLUSIONS: The current results indicated that GELOX followed by involved-field radiation therapy can be an effective and feasible treatment strategy for patients with stage IE/IIE ENKTL of the upper aerodigestive tract. These results will require further investigation in larger prospective trials. Cancer 2013. [copy 2012 American Cancer Society. Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a distinct subtype of natural killer cell lymphoma in which, to date, optimal treatment strategies and prognosis have not been fully defined. Combined gemcitabine, oxaliplatin, and L-asparaginase followed by involved-field radiation therapy can be an effective and feasible treatment strategy for patients with stage IE/IIE ENKTL of the upper aerodigestive tract.
language: English
source:
identifier: ISSN: 0008-543X
fulltext: fulltext
issn:
  • 0008-543X
  • 0008543X
url: Link


@attributes
ID244110620
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid317369772
sourceidgale_ofa
recordidTN_gale_ofa317369772
sourceformatXML
sourcesystemOther
pqid1273251914
galeid317369772
display
typearticle
titleFirst-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.(Hematologic Malignancies)(Report)
creatorWang, Liang ; Wang, Zhi - Hui ; Chen, Xiao - Qin ; Li, Ya - Jun ; Wang, Ke - Feng ; Xia, Yun - Fei ; Xia, Zhong - Jun
ispartofCancer, Jan 15, 2013, Vol.119(2), p.348(8)
identifierISSN: 0008-543X
subjectT Cell Lymphoma -- Research ; T Cell Lymphoma -- Drug Therapy ; T Cell Lymphoma -- Patient Outcomes ; Antineoplastic Agents -- Research ; Antineoplastic Agents -- Dosage And Administration
languageEnglish
source
descriptionBACKGROUND: Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a distinct subtype of non-Hodgkin lymphoma in which the upper aerodigestive tract is the most commonly involved site. To date, optimal treatment strategies and prognosis for patients with ENKTL have not been fully defined. METHODS: This prospective study was conducted to evaluate the efficacy and safety profiles of first-line combined gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE ENKTL. The primary endpoints were the complete response rate, the objective response rate, and toxicities. Secondary endpoints were overall survival and progression-free survival. RESULTS: Twenty-seven patients with newly diagnosed ENKTL were enrolled and completed the entire course of treatment. At the end of treatment, the overall response rate was 96.3%, including 20 patients (74.1%) who attained a complete response and 6 patients (22.2%) who attained a partial response. No patients developed disease progression during therapy. Grade 1 and 2 toxicities were frequent during GELOX, but grade 3 and 4 toxicities were few, and no treatment-related deaths occurred. At a median follow-up of 27.37 months, 7 patients (25.9%) experienced disease progression, and 4 of those patients died of disease. The rates of 2-year overall and progression-free survival were both 86%, and patients who attained a complete response at the end of treatment had significantly longer progression-free survival (P = .012) and overall survival (P = .021) than patients who did not attain a complete response. CONCLUSIONS: The current results indicated that GELOX followed by involved-field radiation therapy can be an effective and feasible treatment strategy for patients with stage IE/IIE ENKTL of the upper aerodigestive tract. These results will require further investigation in larger prospective trials. Cancer 2013. [copy 2012 American Cancer Society. Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a distinct subtype of natural killer cell lymphoma in which, to date, optimal treatment strategies and prognosis have not been fully defined. Combined gemcitabine, oxaliplatin, and L-asparaginase followed by involved-field radiation therapy can be an effective and feasible treatment strategy for patients with stage IE/IIE ENKTL of the upper aerodigestive tract.
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
scope
0gale_onefilea
1OneFile
creatorcontrib
0Wang, Liang
1Wang, Zhi-hui
2Chen, Xiao-qin
3Li, Ya-jun
4Wang, Ke-feng
5Xia, Yun-fei
6Xia, Zhong-jun
titleFirst-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.(Hematologic Malignancies)(Report)
subject
0T cell lymphoma--Research
1T cell lymphoma--Drug therapy
2T cell lymphoma--Patient outcomes
3Antineoplastic agents--Research
4Antineoplastic agents--Dosage and administration
52834
6Pharmaceutical preparations
7Pharmaceutical Preparation Manufacturing
8325412
general
0English
1J.B. Lippincott Company
2Cengage Learning, Inc.
sourceidgale_ofa
recordidgale_ofa317369772
issn
00008-543X
10008543X
rsrctypearticle
creationdate2013
recordtypearticle
addtitleCancer
searchscopeOneFile
lsr30VSR-Enriched:[doi, galeid, pqid, eissn, description, pages]
sort
titleFirst-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.(Hematologic Malignancies)(Report)
authorWang, Liang ; Wang, Zhi - Hui ; Chen, Xiao - Qin ; Li, Ya - Jun ; Wang, Ke - Feng ; Xia, Yun - Fei ; Xia, Zhong - Jun
creationdate20130115
facets
frbrgroupid6066228155570329335
frbrtype5
languageeng
creationdate2013
topic
0T Cell Lymphoma–Research
1T Cell Lymphoma–Drug Therapy
2T Cell Lymphoma–Patient Outcomes
3Antineoplastic Agents–Research
4Antineoplastic Agents–Dosage And Administration
collectionOneFile (GALE)
prefilterarticles
rsrctypearticles
creatorcontrib
0Wang, Liang
1Wang, Zhi - Hui
2Chen, Xiao - Qin
3Li, Ya - Jun
4Wang, Ke - Feng
5Xia, Yun - Fei
6Xia, Zhong - Jun
jtitleCancer
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Wang, Liang
1Wang, Zhi-hui
2Chen, Xiao-qin
3Li, Ya-jun
4Wang, Ke-feng
5Xia, Yun-fei
6Xia, Zhong-jun
atitleFirst-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.(Hematologic Malignancies)(Report)
jtitleCancer
risdate20130115
volume119
issue2
spage348
issn0008-543X
genrearticle
ristypeJOUR
pubJ.B. Lippincott Company
lad01gale_ofa
doi10.1002/cncr.27752
pages348-355
eissn10970142
date2013-01-15